TWi Biotechnology
Taipei, Taiwan· Est.
Taiwan biotech repurposing approved drugs for rare dermatologic and CNS indications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech repurposing approved drugs for rare dermatologic and CNS indications.
DermatologyCNS DisordersRare DiseasesPsychiatryImmunology
Technology Platform
Drug repurposing via FDA 505(b)(2) pathway combined with novel formulations (e.g., topical gels) and prodrug designs to create new indications from existing molecules.
Opportunities
Successful Phase III data for AC-203 and continued efficacy signals for NORA520 could enable lucrative licensing deals or acquisition, while the JAK‑gel platform may attract dermatology partnerships.
Risk Factors
Clinical trial outcomes, regulatory approval uncertainty, and limited commercial infrastructure pose significant risks to value realization.
Competitive Landscape
TWiB competes with larger biotech and pharma firms in rare dermatology and CNS spaces; its differentiation lies in repurposing and formulation innovation that shortens development timelines.